Compare · AARD vs MRK
AARD vs MRK
Side-by-side comparison of Aardvark Therapeutics Inc. (AARD) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AARD and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $364.26B, about 12514.7x AARD ($29.1M).
- MRK has been more active in the news (18 items in the past 4 weeks vs 7 for AARD).
- MRK has more recent analyst coverage (25 ratings vs 17 for AARD).
- Company
- Aardvark Therapeutics Inc.
- Merck & Company Inc.
- Price
- -
- -
- Market cap
- $29.1M
- $364.26B
- 1M return
- -
- +1.70%
- 1Y return
- -
- +59.16%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 7
- 18
- Recent ratings
- 17
- 25
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest AARD
- Aardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Aardvark Therapeutics Inc.
- Chief Executive Officer Lee Tien-Li was granted 793,951 stock options and returned 793,951 stock options to the company (SEC Form 4)
- Officer Sun Nelson was granted 304,094 stock options and returned 304,094 stock options to the company (SEC Form 4)
- Chief Medical Officer Jaiman Manasi was granted 374,560 stock options and returned 374,560 stock options to the company (SEC Form 4)
- Aardvark Therapeutics downgraded by Raymond James
- SEC Form 8-K filed by Aardvark Therapeutics Inc.
- Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
- SEC Form 8-K filed by Aardvark Therapeutics Inc.
Latest MRK
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
- FDA Approval for WELIREG issued to MERCK SHARP DOHME
- SEC Form 10-Q filed by Merck & Company Inc.
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- SEC Form 4 filed by Director Diaz Paul J
- New insider Diaz Paul J claimed ownership of 296 shares (SEC Form 3)
- Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations